NCT02790762

Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis

A Phase I Study of Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Pneumoconiosis.

Detailed description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into mature cells typical of several tissues, which have been confirmed in in vivo and in vitro experiments. To investigate the effects of hUC-MSC treatment for Pneumoconiosis, 10 patients with Pneumoconiosis will be enrolled and receive 4 times of hUC-MSC transplantation.

Conditions

• Pneumoconiosis

Interventions

Type	Name	Description
BIOLOGICAL	Human umbilical cord mesenchymal stem cells	A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.

Timeline

• Start date: 2016-06-01
• Primary completion: 2017-06-01
• Completion: 2017-10-01
• First posted: 2016-06-06
• Last updated: 2016-06-06

Locations

1 site across 1 country: China